Literature DB >> 31905379

Growth and Distribution of Buprenorphine-Waivered Providers in the United States, 2007-2017.

Ryan K McBain1, Andrew Dick1, Mark Sorbero2, Bradley D Stein2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31905379      PMCID： PMC7217729          DOI： 10.7326/M19-2403

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  3 in total

Review 1.  A scoping review of opioid misuse in the rural United States.

Authors:  Laura C Palombi; Catherine A St Hill; Martin S Lipsky; Michael T Swanoski; M Nawal Lutfiyya
Journal:  Ann Epidemiol       Date:  2018-06-02       Impact factor: 3.797

2.  Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder.

Authors:  Christopher M Jones; Elinore F McCance-Katz
Journal:  Addiction       Date:  2018-10-15       Impact factor: 6.526

3.  Medication Assisted Treatment for Opioid Use Disorders Reporting Requirements. Final rule.zzm321990

Authors: 
Journal:  Fed Regist       Date:  2016-09-27
  3 in total
  16 in total

1.  Patient, prescriber, and Community factors associated with filled naloxone prescriptions among patients receiving buprenorphine 2017-18.

Authors:  Bradley D Stein; Christopher M Jones; Rosanna Smart; Flora Sheng; Mark Sorbero
Journal:  Drug Alcohol Depend       Date:  2021-02-03       Impact factor: 4.492

2.  Medicaid prevalence and opioid use disorder treatment access disparities.

Authors:  Michael R Richards; Ashley A Leech; Bradley D Stein; Melinda B Buntin; Stephen W Patrick
Journal:  Health Serv Res       Date:  2021-12-18       Impact factor: 3.402

3.  Population-based estimates of geographic accessibility of medication for opioid use disorder by substance use disorder treatment facilities from 2014 to 2020.

Authors:  Jonathan Cantor; David Powell; Aaron Kofner; Bradley D Stein
Journal:  Drug Alcohol Depend       Date:  2021-09-27       Impact factor: 4.492

4.  Comparing the feasibility of four web-based recruitment strategies to evaluate the treatment preferences of rural and urban adults who misuse non-prescribed opioids.

Authors:  Elizabeth C Saunders; Alan J Budney; Patricia Cavazos-Rehg; Emily Scherer; Lisa A Marsch
Journal:  Prev Med       Date:  2021-09-07       Impact factor: 4.018

Review 5.  The state of the science in opioid policy research.

Authors:  Megan S Schuler; Sara E Heins; Rosanna Smart; Beth Ann Griffin; David Powell; Elizabeth A Stuart; Bryce Pardo; Sierra Smucker; Stephen W Patrick; Rosalie Liccardo Pacula; Bradley D Stein
Journal:  Drug Alcohol Depend       Date:  2020-06-27       Impact factor: 4.492

6.  Buprenorphine prescriber monthly patient caseloads: An examination of 6-year trajectories.

Authors:  Irineo Cabreros; Beth Ann Griffin; Brendan Saloner; Adam J Gordon; Rose Kerber; Bradley D Stein
Journal:  Drug Alcohol Depend       Date:  2021-09-22       Impact factor: 4.492

7.  Opioid treatment program and community pharmacy collaboration for methadone maintenance treatment: results from a feasibility clinical trial.

Authors:  Li-Tzy Wu; William S John; Eric D Morse; Steve Adkins; Jennifer Pippin; Robert K Brooner; Robert P Schwartz
Journal:  Addiction       Date:  2021-08-16       Impact factor: 6.526

8.  It will end in tiers: A strategy to include "dabblers" in the buprenorphine workforce after the X-waiver.

Authors:  Brendan Saloner; Barbara Andraka Christou; Adam J Gordon; Bradley D Stein
Journal:  Subst Abus       Date:  2021-04-02       Impact factor: 3.716

9.  Development of an unannounced standardized patient protocol to evaluate opioid use disorder treatment in pregnancy for American Indian and rural communities.

Authors:  A Taylor Kelley; Marcela C Smid; Jacob D Baylis; Elizabeth Charron; Amy E Binns-Calvey; Shayla Archer; Saul J Weiner; Lori Jo Begaye; Gerald Cochran
Journal:  Addict Sci Clin Pract       Date:  2021-06-25

10.  Disparities in receipt of medications for opioid use disorder among pregnant women.

Authors:  Laura E Henkhaus; Melinda B Buntin; Sarah Clark Henderson; Pikki Lai; Stephen W Patrick
Journal:  Subst Abus       Date:  2021-07-16       Impact factor: 3.716
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.